Kneecapping Big Pharma ep. 32 

#InjuriousPersonaities #KneecappingBigPharma
Deposition of Karen Harper, senior director of DEA compliance
Staubus v Purdue et al
In re National Prescription Opiate Litigation
The DEA sets API quotas (or active pharmaceutical ingredients) a couple times a year for a given manufacturer, which ultimately determines how many sales accounts they’re allowed to have in a state at one time. Mallinckrodt is required to report any diversions to the DEA, which helps the DEA set those quotas. Time and again this witness does not recall some document or confirm its authenticity when it is she who sent it or composed it. And in order to identify diversions, her subordinates have to monitor “suspicious”/ unusually high orders from their distributors. But now, once the pill mills have all been shut down, it seems that no one has any recollection whatsoever of what orders were or were not suspicious. So you decide: Was the SOMT about due diligence or just a box-checking exercise to satisfy the DEA?